Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Terns Pharmaceuticals, Inc. (TERN) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Terns Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1831363.
Total stock buying since 2021: $94,100,277.
Total stock sales since 2021: $12,930,825.
Total stock option exercises since 2021: $111,839.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 48,314 | $186,590 | 38,474 | $217,090 | 0 | $0 |
| 2024 | 503,982 | $5,167,109 | 589,991 | $4,463,735 | 42,000 | $111,839 |
| 2023 | 27,813 | $42,734 | 0 | $0 | 0 | $0 |
| 2022 | 16,196,281 | $53,173,844 | 1,500,000 | $8,250,000 | 0 | $0 |
| 2021 | 2,090,000 | $35,530,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-07 | 0 | $0 | 853 | $3,639 | 0 | $0 |
| 2025-06 | 48,314 | $186,590 | 0 | $0 | 0 | $0 |
| 2025-04 | 0 | $0 | 952 | $2,365 | 0 | $0 |
| 2025-01 | 0 | $0 | 36,669 | $211,086 | 0 | $0 |
| 2024-12 | 15,450 | $110,467 | 0 | $0 | 0 | $0 |
| 2024-11 | 2,760 | $14,103 | 0 | $0 | 0 | $0 |
| 2024-09 | 476,190 | $4,999,995 | 27,235 | $282,350 | 27,235 | $84,967 |
| 2024-08 | 0 | $0 | 15,000 | $113,583 | 0 | $0 |
| 2024-07 | 0 | $0 | 127,093 | $1,270,944 | 14,765 | $26,872 |
| 2024-05 | 9,582 | $42,544 | 0 | $0 | 0 | $0 |
| 2024-04 | 0 | $0 | 420,663 | $2,796,858 | 0 | $0 |
| 2023-11 | 1,486 | $5,616 | 0 | $0 | 0 | $0 |
| 2023-05 | 26,327 | $37,118 | 0 | $0 | 0 | $0 |
| 2022-12 | 2,344,826 | $16,999,984 | 0 | $0 | 0 | $0 |
| 2022-11 | 9 | $12 | 1,500,000 | $8,250,000 | 0 | $0 |
| 2022-09 | 1,200,000 | $4,320,000 | 0 | $0 | 0 | $0 |
| 2022-08 | 12,628,478 | $31,820,086 | 0 | $0 | 0 | $0 |
| 2022-05 | 22,968 | $33,762 | 0 | $0 | 0 | $0 |
| 2021-02 | 2,090,000 | $35,530,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-01 | Kuriakose Emil (Chief Medical Officer) | Sale | 853 | 4.27 | 3,639 |
| 2025-06-27 | Gengos Andrew (Chief Financial Officer) | Buy | 10,000 | 3.93 | 39,280 |
| 2025-06-25 | Burroughs Amy L. (Chief Executive Officer) | Buy | 23,314 | 3.87 | 90,225 |
| 2025-06-16 | Gengos Andrew (Chief Financial Officer) | Buy | 5,000 | 3.95 | 19,735 |
| 2025-06-13 | Gengos Andrew (Chief Financial Officer) | Buy | 10,000 | 3.73 | 37,350 |
| 2025-04-01 | Kuriakose Emil (Chief Medical Officer) | Sale | 952 | 2.48 | 2,365 |
| 2025-01-06 | Quigley Jill M. | Sale | 8,760 | 5.79 | 50,755 |
| 2025-01-06 | Vignola Mark J. (Chief Financial Officer) | Sale | 9,059 | 5.79 | 52,496 |
| 2025-01-02 | Kuriakose Emil (Chief Medical Officer) | Sale | 4,481 | 5.71 | 25,608 |
| 2025-01-02 | Quigley Jill M. | Sale | 6,240 | 5.72 | 35,705 |
| 2025-01-02 | Vignola Mark J. (Chief Financial Officer) | Sale | 8,129 | 5.72 | 46,522 |
| 2024-12-05 | Burroughs Amy L. (Chief Executive Officer) | Buy | 15,450 | 7.15 | 110,467 |
| 2024-11-30 | Jung Melita Sun (Chief Business Officer) | Buy | 2,250 | 5.11 | 11,497 |
| 2024-11-30 | Burroughs Amy L. (Chief Executive Officer) | Buy | 510 | 5.11 | 2,606 |
| 2024-09-12 | Lu Hongbo | Buy | 476,190 | 10.50 | 4,999,995 |
| 2024-09-10 | Vignola Mark J. (Chief Financial Officer) | Sale | 10,000 | 11.00 | 110,000 |
| 2024-09-10 | Vignola Mark J. (Chief Financial Officer) | Option Ex | 10,000 | 5.36 | 53,600 |
| 2024-09-09 | Quigley Jill M. | Sale | 17,235 | 10.00 | 172,350 |
| 2024-09-09 | Quigley Jill M. | Option Ex | 17,235 | 1.82 | 31,367 |
| 2024-08-02 | Quigley Jill M. | Sale | 8,857 | 7.50 | 66,436 |
| 2024-08-01 | Quigley Jill M. | Sale | 6,143 | 7.67 | 47,147 |
| 2024-07-16 | Orbimed Genesis Gp Llc | Sale | 5,188 | 10.00 | 51,880 |
| 2024-07-16 | Quigley Jill M. | Sale | 400 | 10.00 | 4,000 |
| 2024-07-16 | Quigley Jill M. | Option Ex | 400 | 1.82 | 728 |
| 2024-07-16 | Gordon Carl L | Sale | 5,188 | 10.00 | 51,880 |
| 2024-07-15 | Orbimed Genesis Gp Llc | Sale | 50,976 | 10.00 | 509,760 |
| 2024-07-15 | Quigley Jill M. | Sale | 14,365 | 10.00 | 143,664 |
| 2024-07-15 | Quigley Jill M. | Option Ex | 14,365 | 1.82 | 26,144 |
| 2024-07-15 | Gordon Carl L | Sale | 50,976 | 10.00 | 509,760 |
| 2024-05-31 | Vignola Mark J. (Chief Financial Officer) | Buy | 4,791 | 4.44 | 21,272 |
| 2024-05-31 | Yoon Seokho Bryan (COO and General Counsel) | Buy | 4,791 | 4.44 | 21,272 |
| 2024-04-03 | Vivo Capital Surplus Fund Viii, L.p. | Sale | 138,066 | 6.20 | 856,009 |
| 2024-04-02 | Vivo Capital Surplus Fund Viii, L.p. | Sale | 101,480 | 6.65 | 674,842 |
| 2024-04-01 | Vivo Capital Surplus Fund Viii, L.p. | Sale | 181,117 | 6.99 | 1,266,007 |
| 2023-11-30 | Vignola Mark J. (Chief Financial Officer) | Buy | 743 | 3.78 | 2,808 |
| 2023-11-30 | Yoon Seokho Bryan (COO and General Counsel) | Buy | 743 | 3.78 | 2,808 |
| 2023-05-31 | Vignola Mark J. (Chief Financial Officer) | Buy | 9,997 | 1.41 | 14,095 |
| 2023-05-31 | Sundaram Senthil Vel (Chief Executive Officer) | Buy | 4,222 | 1.41 | 5,952 |
| 2023-05-31 | Yoon Seokho Bryan (COO and General Counsel) | Buy | 9,997 | 1.41 | 14,095 |
| 2022-12-23 | Orbimed Genesis Gp Llc | Buy | 275,862 | 7.25 | 1,999,998 |
| 2022-12-23 | Lu Hongbo | Buy | 758,620 | 7.25 | 5,499,995 |
| 2022-12-23 | Vivo Capital Surplus Fund Viii, L.p. | Buy | 758,620 | 7.25 | 5,499,995 |
| 2022-12-23 | Gordon Carl L | Buy | 275,862 | 7.25 | 1,999,998 |
| 2022-11-30 | Vignola Mark J. (Chief Financial Officer) | Buy | 3 | 1.41 | 4 |
| 2022-11-30 | Sundaram Senthil Vel (Chief Executive Officer) | Buy | 3 | 1.41 | 4 |
| 2022-11-30 | Yoon Seokho Bryan (COO and General Counsel) | Buy | 3 | 1.41 | 4 |
| 2022-11-23 | Oriental Spring Venture Ltd (10% Owner) | Sale | 1,500,000 | 5.50 | 8,250,000 |
| 2022-09-07 | Lu Hongbo | Buy | 600,000 | 3.60 | 2,160,000 |
| 2022-09-07 | Vivo Capital Surplus Fund Viii, L.p. | Buy | 600,000 | 3.60 | 2,160,000 |
| 2022-08-16 | Orbimed Genesis Gp Llc | Buy | 3,690,000 | 2.42 | 8,929,800 |
| 2022-08-16 | Lu Hongbo | Buy | 1,500,000 | 2.42 | 3,630,000 |
| 2022-08-16 | Vivo Capital Surplus Fund Viii, L.p. | Buy | 1,500,000 | 2.42 | 3,630,000 |
| 2022-08-16 | Gordon Carl L | Buy | 3,690,000 | 2.42 | 8,929,800 |
| 2022-08-15 | Lu Hongbo | Buy | 1,218 | 2.99 | 3,641 |
| 2022-08-15 | Vivo Capital Surplus Fund Viii, L.p. | Buy | 1,218 | 2.99 | 3,641 |
| 2022-08-12 | Lu Hongbo | Buy | 1,123,021 | 2.98 | 3,346,602 |
| 2022-08-12 | Vivo Capital Surplus Fund Viii, L.p. | Buy | 1,123,021 | 2.98 | 3,346,602 |
| 2022-05-31 | Vignola Mark J. (Chief Financial Officer) | Buy | 7,656 | 1.47 | 11,254 |
| 2022-05-31 | Sundaram Senthil Vel (Chief Executive Officer) | Buy | 7,656 | 1.47 | 11,254 |
| 2022-05-31 | Yoon Seokho Bryan (COO and General Counsel) | Buy | 7,656 | 1.47 | 11,254 |
| 2021-02-09 | Orbimed Advisors Iii Ltd | Buy | 475,000 | 17.00 | 8,075,000 |
| 2021-02-09 | Vivo Opportunity Fund, L.p. | Buy | 475,000 | 17.00 | 8,075,000 |
| 2021-02-09 | Gordon Carl L | Buy | 475,000 | 17.00 | 8,075,000 |
| 2021-02-09 | Deerfield Mgmt L.p. | Buy | 665,000 | 17.00 | 11,305,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of TERN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Terns Pharmaceuticals, Inc. (symbol TERN, CIK number 1831363) see the Securities and Exchange Commission (SEC) website.